- Sections
- C - Chimiemétallurgie
- C07D - Composés hétérocycliques
- C07D 215/36 - Atomes de soufre
Détention brevets de la classe C07D 215/36
Brevets de cette classe: 314
Historique des publications depuis 10 ans
|
15
|
20
|
24
|
21
|
16
|
10
|
21
|
18
|
10
|
2
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Agios Pharmaceuticals, Inc | 219 |
15 |
| Amgen Inc. | 4290 |
12 |
| Bristol-myers Squibb Company | 4795 |
8 |
| Novartis AG | 10494 |
7 |
| Hinova Pharmaceuticals Inc. | 99 |
7 |
| Jiangsu Hengrui Medicine Co., Ltd. | 701 |
7 |
| Pharmaxis Ltd | 34 |
6 |
| Oxford Drug Design Limited | 10 |
6 |
| Korea Research Institute of Chemical Technology | 1432 |
5 |
| Galapagos NV | 276 |
4 |
| Galderma Research & Development | 377 |
4 |
| National Cancer Center | 333 |
4 |
| The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth, Near Dublin | 172 |
4 |
| Southern Research Institute | 208 |
4 |
| The United States Government AS represented by The Department of Veterans Affairs | 1265 |
4 |
| The University of Melbourne | 558 |
4 |
| The University of Queensland | 667 |
4 |
| Inflazome Limited | 84 |
4 |
| AbbVie Global Enterprises Ltd. | 14 |
4 |
| Merck Patent GmbH | 5727 |
3 |
| Autres propriétaires | 198 |